Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old

Breast

Volumn 19, Issue 6, 2010, Pages 456-461

  Karihtala, Peeter ^a   Winqvist, Robert ^a   Bloigu, Risto ^b   Jukkola Vuorinen, Arja ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; Estrogen receptor; Hormone therapy; Lymph node ratio; Survival; Young

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 78349312269     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.05.001     Document Type: Article

References (41)

1. Mintzer D., Glassburg J., Mason B.A., Sataloff D. Breast cancer in the very young patients: a multidisciplinary case presentation. Oncology 2002, 7:547-554.
2. Han W., Kim S.W., Park I.A., Kang D., Kim S.W., Youn Y.K., et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004, 4:82.
3. Agarwal G., Pradeep P.V., Agarwal V., Yip C.H., Cheung P.S. Spectrum of breast cancer in Asian women. World J Surg 2007, 31:1031-1040.
4. Dubsky P.C., Gnant M.F., Taucher S., Roka S., Kandioler D., Pichler-Gebhard B., et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 2002, 3:65-72.
5. Kalfon B., Fineberg S., Gu Y., Anand K., Dalal A., Jones J., et al. Microvessel density and p53 overexpression in young women with breast cancer: a case-control study. Clin Breast Cancer 2001, 2:67-72.
6. de la Rochefordiere A., Asselain B., Campana F., Scholl S.M., Fenton J., Vilcoq J.R., et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993, 341:1039-1043.
7. Fredholm H., Eaker S., Frisell J., Holmberg L., Fredriksson I., Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009, 4:e7695.
8. Adami H.O., Malker B., Holmberg L., Persson I., Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986, 315:559-563.
9. Bertheau P., Steinberg S.M., Merino M.J. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1998, 29:323-329.
10. Fowble B.L., Schultz D.J., Overmoyer B., Solin L.J., Fox K., Jardines L., et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994, 30:23-33.
11. Elkum N., Dermime S., Ajarim D., Al-Zahrani A., Alsayed A., Tulbah A., et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007, 5:222.
12. Ahn S.H., Son B.H., Kim S.W., Kim S.I., Jeong J., Ko S.S., et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea - a report from the Korean Breast Cancer Society. J Clin Oncol 2007, 25:2360-2368.
13. Kroman N., Jensen M.B., Wohlfahrt J., Mouridsen H.T., Andersen P.K., Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br Med J 2000, 320:474-478.
14. Winchester D.P., Osteen R.T., Menck H.R. The national Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996, 78:1838-1843.
15. Kollias J., Elston C.W., Ellis I.O., Robertson J.F., Blamey R.W. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 1997, 75:1318-1323.
16. Walker R.A., Lees E., Webb M.B., Dearing S.J. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996, 74:1796-1800.
17. Karihtala P., Mäntyniemi A., Kang S.W., Kinnula V.L., Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003, 9:3418-3424.
18. Isola J., Tanner M., Forsyth A., Cooke T.G., Watters A.D., Bartlett J.M. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004, 10:4793-4798.
19. Chung M., Chang H.R., Bland K.I., Wanebo H.J. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996, 77:97-103.
20. Yildirim E., Dalgic T., Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol 2000, 74:267-272.
21. Gonzalez-Angulo A.M., Broglio K., Kau S.W., Eralp Y., Erlichman J., Valero V., et al. Women age\or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 2005, 103:2466-2472.
22. Nixon A.J., Neuberg D., Hayes D.F., Gelman R., Connolly J.L., Schnitt S., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994, 12:888-894.
23. Guerra I., Algorta J., Díaz de Otazu R., Pelayo A., Fariña J. Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol 2003, 56:323-327.
24. Hartley M.C., McKinley B.P., Rogers E.A., Kalbaugh C.A., Messich H.S., Blackhurst D.W., et al. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study. Am Surg 2006, 72:1189-1194.
25. Choi D.H., Kim S., Rimm D.L., Carter D., Haffty B.G. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J 2005, 11:404-411.
26. Jmor S., Al-Sayer H., Heys S.D. Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Edinb 2002, 47:693-699.
27. van der Wal B.C., Butzelaar R.M., van der Meij S., Boermeester M.A. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002, 28:481-489.
28. Vinh-Hung V., Verkooijen H.M., Fioretta G., Neyroud-Caspar I., Rapiti E., Vlastos G., et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 2009, 27:1062-1068.
29. Hatoum H.A., Jamali F.R., El-Saghir N.S., Musallam K.M., Seoud M., Dimassi H., et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol 2009, 16:3388-3395.
30. Buchanan C.L., Dorn P.L., Fey J., Giron G., Naik A., Mendez J., et al. Locoregional recurrence after mastectomy. J Am Coll Surg 2006, 203:469-474.
31. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347:1227-1232.
32. Freedman G.M., Hanlon A.L., Fowble B.L., Anderson P.R., Nicolaou N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol 2002, 20:4015-4021.
33. Neuschatz A.C., DiPetrillo T., Safaii H., Price L.L., Schmidt-Ullrich R.K., Wazer D.E. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 2003, 97:30-39.
34. Loman N., Johannsson O., Kristoffersson U., Olsson H., Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001, 93:1215-1223.
35. Zakhartseva L.M., Gorovenko N.G., Podolskaya S.V., Anikusko N.F., Lobanova O.E., Pekur K.A., et al. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations. Exp Oncol 2009, 31:174-178.
36. Alkner S., Bendahl P.O., Fernö M., Nordenskjöld B., Rydén L. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer 2009, 45:2496-2502. South Swedish and South-East Swedish Breast Cancer Groups.
37. Colleoni M., Rotmensz N., Robertson C., Orlando L., Viale G., Renne G., et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002, 13:273-279.
38. Gajdos C., Tartter P.I., Bleiweiss I.J., Bodian C., Brower S.T. Stage 0 to stage III breast cancer in young women. J Am Coll Surg 2000, 190:523-529.
39. Goldhirsch A., Gelber R.D., Yothers G., Gray R.J., Green S., Bryant J., et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monographs 2001, 30:44-51.
40. Burdette-Radoux S., Muss H.B. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?. Clin Breast Cancer 2009, 9:S37-S41.
41. Pagani O., O'Neill A., Castiglione M., Gelber R.D., Goldhirsch A., Rudenstam C.M., et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998, 34:632-640.